Skip to main content

Advertisement

Table 2 Univariate analysis of influence of clinical characteristics on overall survival in hepatocellular patients

From: IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

   OS  
Characteristics N Median survival (months) Survival (%) Log-rank
Age (years)
  < 65 100 36.83 75.00% 0.282
65 117 41.42 80.34%  
Gender
 Female 58 38.37 76.27% 0.631
 Male 159 40.49 78.48%  
Differentiation
 Well, Moderate 117 40.69 78.45% 0.731
 Undifferentitation, Poor 100 39.26 77.23%  
Stage
 I, II 180 42.22 82.49% < 0.001
 III, IV 37 30.13 57.50%  
Hepatitis B surface antigen
 Negative 106 40.33 79.25% 0.617
 Positive 111 39.08 76.58%  
Hepatits C virus
 Negative 150 39.14 76.67% 0.489
 Positive 67 41.1 80.60%  
Tumor Number
 Single 177 40.25 77.78% 0.926
 Multiple 40 37.17 78.38%  
Tumor size
  < 5 cm 140 49.79 86.43% < 0.001
5 cm 77 33.12 62.34%  
Relapse
 - 196 41.31 81.54% < 0.001
 + 21 28.79 45.00%